In a cohort of 177 HER2-amplified breast carcinomas, low HER3 expression was related to clinicopathological characteristics known to predict poor clinical outcome, with the exception of the cell proliferation marker Ki67, which was not shown to associate with HER3 (Table 5). This evidence concerns the gene ERBB2 and breast carcinoma.